Over a decade of research may soon yield product

By Patrick Anderson
PBN Staff Writer

It’s been a dozen years since Brown University Warren Alpert Medical School professors Yow-Pin Lim and Douglas Hixson made the jump from scientists to entrepreneurs with the founding of ProThera Biologics LLC. More

To continue reading this article, please do one of the following.



Focus: TECHNOLOGY

Over a decade of research may soon yield product

PBN PHOTO/TRACY JENKINS
LOGICAL APPROACH: Yow-Pin Lim, foreground, founder of ProThera Biologics with ProThera lab scientists Andre Santoso, right, and Ryan Denckewicz.

By Patrick Anderson
PBN Staff Writer

Posted 11/18/13

It’s been a dozen years since Brown University Warren Alpert Medical School professors Yow-Pin Lim and Douglas Hixson made the jump from scientists to entrepreneurs with the founding of ProThera Biologics LLC.

Now, backed by more than $8 million in state and federal research investments, ProThera can see a day when its work on life-threatening diseases will become a treatment.

The East Providence startup is encouraged by the results of an animal study funded by the National Institutes of Health into whether its technology is an effective protection against anthrax.

The company recently moved into a new office and laboratory space in the former FujiFilms building on Massasoit Avenue in the waterfront district, which will allow it to scale up production of trial materials.

And after being funded through government grants and Rhode Island’s Slater Technology Fund to this point, Lim said ProThera is now looking for investors. “When we started, we didn’t know what this molecule could do,” Lim said, “and now we know more clearly the potential. The approval we got in principle and in several animal models gives us more confidence, we are on the right track.”

ProThera’s first chance to implement its research could come next year with the conclusion of the animal study, which is expected to provide the data needed to market a treatment to the U.S. government as a bio-defense agent.

Like most biotech concerns, reaching a broader medical market will take still longer due to the demands of the Food and Drug Administration pharmaceutical approval process.

“Right now we are testing efficacy on anthrax, but it could be avian flu or swine flu or a number of biological agents – the problem now is it is one bug one drug, but potentially how many drugs can be bioweapons,” Lim said. “Biodefense is one thing, but our focus ultimately is sepsis, systemic inflammation. We can use this for a whole range of clinical diseases.”

The idea behind ProThera Biologics is actually a set of proteins produced by the liver, called inter-alpha inhibitors, whose properties were discovered accidentally in the labs of Rhode Island Hospital.

Next Page
Calendar
PBN Hosted
Events

Join PBN for the best networking event and party of the winter - January 15, 2015 - the Book of Lists Party at the Providence Public Library. Reserve your spot early!
  • Best Places to Work
    Enrollment is now open for the 7th annual Best Places to Work program. Winners w ...
  • Manufacturing Awards
    Applications are now being accepted for the 2nd Annual Manufacturing Awards. Dea ...
Advertisement
Purchase Data
Book of Lists
Lists
Book of Lists cover
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.
Data icons
Data can be purchased as single lists, in either Excel or PDF format; the entire database of the published book, in Excel format; or a printed copy of the Book of Lists.
  • Purchase an e-File of a single list
  •  
  • Purchase an e-File of the entire Book of Lists database
  •  
  • Purchase a printed copy of the Book of Lists
  •  
    National
    Local
    Latest News
    Advertisement